{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:53:16Z","timestamp":1780984396434,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-01872-w","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T09:23:36Z","timestamp":1739265816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data"],"prefix":"10.1186","volume":"25","author":[{"given":"Aki","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohide","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nagamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Hisaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"24","key":"1872_CR1","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehx144","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"9753","key":"1872_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Collaboration, Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT), Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","journal-title":"Lancet"},{"key":"1872_CR3","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA, \/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol. Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046-e1081. https:\/\/doi.org\/10.1161\/CIR.0000000000000625","DOI":"10.1161\/CIR.0000000000000625"},{"issue":"2","key":"1872_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","volume":"3","author":"JE Hokanson","year":"1996","unstructured":"Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213\u20139.","journal-title":"J Cardiovasc Risk"},{"issue":"3","key":"1872_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299\u2013308. https:\/\/doi.org\/10.1001\/jama.298.3.299.","journal-title":"JAMA"},{"issue":"47","key":"1872_CR6","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551.","journal-title":"Eur Heart J"},{"key":"1872_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/VHRM.S104369","volume":"12","author":"PP Toth","year":"2016","unstructured":"Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171\u201383. https:\/\/doi.org\/10.2147\/VHRM.S104369.","journal-title":"Vasc Health Risk Manag"},{"key":"1872_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/ATVBAHA.118.311999","volume":"39","author":"Y Matsuura","year":"2019","unstructured":"Matsuura Y, Kanter JE, Bornfeldt KE. Highlighting residual atherosclerotic cardiovascular disease risk. Arterioscler Thromb Vasc Biol. 2019;39:e1\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311999.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1872_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/2047487319887578","volume":"27","author":"MB Elshazly","year":"2020","unstructured":"Elshazly MB, Mani P, Nissen S, Brennan DM, Clark D, Martin S, et al. Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. Eur J Prev Cardiol. 2020;27(1):1091\u2013100. https:\/\/doi.org\/10.1177\/2047487319887578.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"1872_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","volume":"45","author":"RS Birjmohun","year":"2005","unstructured":"Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2):185\u201397. https:\/\/doi.org\/10.1016\/j.jacc.2004.10.031.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"1872_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","volume":"140","author":"NA Marston","year":"2019","unstructured":"Marston NA, Giugliano RP, Im K, Silverman MG, O\u2019Donoghue ML, Wiviott SD, et al. Association between triglyceride lowering and reduction of Cardiovascular Risk Across multiple lipid-lowering therapeutic classes: a systematic review and Meta-regression analysis of Randomized controlled trials. Circulation. 2019;140(16):1308\u201317. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041998.","journal-title":"Circulation"},{"issue":"1","key":"1872_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16(1):124. https:\/\/doi.org\/10.1186\/s12933-017-0602-y.","journal-title":"Cardiovasc Diabetol"},{"key":"1872_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, et al. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36\u201343. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.032.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1872_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","volume":"22","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug Concept and its clinical applications for Dyslipidemia and Metabolic diseases. Curr Atheroscler Rep. 2020;22(1):5. https:\/\/doi.org\/10.1007\/s11883-020-0823-5.","journal-title":"Curr Atheroscler Rep"},{"key":"1872_CR15","doi-asserted-by":"publisher","unstructured":"Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018;25(9):846\u2013984. https:\/\/doi.org\/10.5551\/jat.GL2017.","DOI":"10.5551\/jat.GL"},{"issue":"6","key":"1872_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","volume":"25","author":"H Arai","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25(6):521\u201338. https:\/\/doi.org\/10.5551\/jat.44412.","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"1872_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, et al. Effects of Pemafibrate, a Novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a Randomized, Double-Blind, Placebo-Controlled, phase 3 trial. Diabetes Care. 2018;41(3):538\u201346. https:\/\/doi.org\/10.2337\/dc17-1589.","journal-title":"Diabetes Care"},{"issue":"22","key":"1872_CR18","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.3390\/ijms20225537","volume":"20","author":"S Yamashita","year":"2019","unstructured":"Yamashita S, Arai H, Yokote K, Araki E, Matsushita M, Nojima T, et al. Efficacy and safety of Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1): pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination. Int J Mol Sci. 2019;20(22):5537. https:\/\/doi.org\/10.3390\/ijms20225537.","journal-title":"Int J Mol Sci"},{"key":"1872_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"1872_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","volume":"20","author":"K Yokote","year":"2021","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, et al. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol. 2021;20(9):96. https:\/\/doi.org\/10.1186\/s12933-021-01291-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1872_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5114\/ceh.2022.120099","volume":"8","author":"S Shinozaki","year":"2022","unstructured":"Shinozaki S, Tahara T, Miura K, Lefor AK, Yamamoto H. Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients. Clin Exp Hepatol. 2022;8(4):278\u201383. https:\/\/doi.org\/10.5114\/ceh.2022.120099.","journal-title":"Clin Exp Hepatol"},{"issue":"3","key":"1872_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12072-022-10453-1","volume":"17","author":"A Morishita","year":"2023","unstructured":"Morishita A, Oura K, Takuma K, Nakahara M, Tadokoro T, Fujita K, et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int. 2023;17(3):606\u201314. https:\/\/doi.org\/10.1007\/s12072-022-10453-1.","journal-title":"Hepatol Int"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01872-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01872-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01872-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:13:43Z","timestamp":1739290423000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01872-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1872"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01872-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study plan was approved by the Okamoto Internal Medicine Clinic Committee and complied with the Declaration of Helsinki and the Ethical Guidelines for Medical Research Involving Human Subjects. The research protocol was reviewed and approved by the Ethics Committee of Juntendo University (no. E22-0436), and written, informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}